Julia E Reid

US Patent:

20030143608, Jul 31, 2003

Filed:

Dec 27, 2002

Appl. No.:

10/331192

Inventors:

Fabiana Filigheddu - Sassari, IT
Julia Reid - Salt Lake City UT, US
Susanne Wagner - Salt Lake City UT, US

Assignee:

Myriad Genetics, Incorporated - Salt Lake City UT

International Classification:

C12Q001/68
A61K031/549

US Classification:

435/006000, 514/223200

Abstract:

Methods of using a genetic polymorphic variation in the human beta-1 adrenergic receptor gene as a drug response marker are presented. Determining the presence or absence of the A145G genetic variation in the human beta-1 adrenergic receptor gene is useful in predicting an individual's relative response to different antihypertensive drugs; optimizing antihypertensive treatment for an individual; selecting candidate human subjects for participation in clinical trials involving antihypertensive drugs; and, predicting the relative responses among a plurality of individuals to an antihypertensive drug.

US Patent:

20070082347, Apr 12, 2007

Filed:

Jun 8, 2006

Appl. No.:

11/450909

Inventors:

Jerry Lanchbury - Salt Lake City UT, US
Alexander Gutin - Sandy UT, US
Andrey Zharkikh - Salt Lake City UT, US
Julia Reid - Salt Lake City UT, US
Kirsten Timms - Salt Lake City UT, US
Susanne Wagner - Salt Lake City UT, US
Ann-Marie Woodland - Roy UT, US

Assignee:

Myriad Genetics, Incorporated - Salt Lake City UT

International Classification:

C12Q 1/68
C07H 21/04
C12M 3/00

US Classification:

435006000, 536023200, 435287200, 257E51020, 977924000

Abstract:

Variants in TLK1, WARS2, ARTS2, MSR, AKAP9, DNAJD1, GOLPH4, RABEP1, TAP2, NARG2, DDX58, CD39, FKBP1a, SRI, XRRA1, IRF5 and AMFR genes are disclosed which are useful as biomarkers for predicting the TLK1, WARS2, ARTS2, MSR, AKAP9, DNAJD1, GOLPH4, RABEP1, TAP2, NARG2, DDX58, CD39, FKBP1a, SRI, XRRA1, IRF5 or AMFR gene expression level and the biological functions associated thereof.

US Patent:

20120041274, Feb 16, 2012

Filed:

Jul 7, 2011

Appl. No.:

13/177887

Inventors:

Steven Stone - Salt Lake City UT, US
Alexander Gutin - Salt Lake City UT, US
Susanne Wagner - Salt Lake City UT, US
Julia Reid - Salt Lake City UT, US

Assignee:

Myriad Genetics, Incorporated - Salt Lake City UT

International Classification:

A61B 5/00
C12Q 1/68
A61P 35/00
C40B 60/12
C40B 40/06
C07G 15/00
C40B 30/00
C12M 1/34

US Classification:

600300, 506 7, 435 61, 4352872, 506 39, 506 16, 514789, 435 612

Abstract:

Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.

US Patent:

20120053253, Mar 1, 2012

Filed:

Jul 7, 2011

Appl. No.:

13/178380

Inventors:

Steven Stone - Salt Lake City UT, US
Alexander Gutin - Salt Lake City UT, US
Susanne Wagner - Salt Lake City UT, US
Julia Reid - Salt Lake City UT, US

Assignee:

Myriad Genetics, Incorporated - Salt Lake City UT

International Classification:

A61K 45/00
C40B 30/04
C40B 60/12
A61P 35/00

US Classification:

514789, 506 9, 506 39

Abstract:

Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.

US Patent:

20130302242, Nov 14, 2013

Filed:

Aug 30, 2011

Appl. No.:

13/819963

Inventors:

Steven Stone - Salt Lake City UT, US
Alexander Gutin - Salt Lake City UT, US
Susanne Wagner - Salt Lake City UT, US
Julia Reid - Salt Lake City UT, US

Assignee:

MYRIAD GENETICS, INC. - Salt Lake City UT

International Classification:

C12Q 1/68

US Classification:

424 111, 506 9, 506 39, 506 16

Abstract:

Biomarkers and methods using the biomarkers for molecular detection and classification of disease and, particularly, molecular markers for cancer diagnosis and prognosis and methods of use thereof are provided.

US Patent:

20220259675, Aug 18, 2022

Filed:

Feb 23, 2022

Appl. No.:

17/678357

Inventors:

- Salt Lake City UT, US
Alexander Gutin - Salt Lake City UT, US
Susanne Wagner - Salt Lake City UT, US
Julia E. Reid - Salt Lake City UT, US

Assignee:

MYRIAD GENETICS, INC. - Salt Lake City UT

International Classification:

C12Q 1/6886

Abstract:

Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.

US Patent:

20230116885, Apr 13, 2023

Filed:

Oct 14, 2022

Appl. No.:

17/966689

Inventors:

- Salt Lake City UT, US
Julia Reid - Salt Lake City UT, US
Ralf Kronenwett - Salt Lake City UT, US
Marsel Scheer - Salt Lake City UT, US

Assignee:

Myriad Genetics, Inc. - Salt Lake City UT

International Classification:

C12Q 1/6886
G16H 70/60
G16H 50/20
G16H 20/10
G16B 25/10
G16B 20/00

Abstract:

Provided herein are methods for predicting chemotherapy benefit. The invention predicts chemotherapy benefit based on the expression analysis of biomarkers, e.g., RNA biomarker transcription analysis, taken from a tumor sample. The biomarker expression data can be combined with clinical variables, e.g., tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.

US Patent:

20210071269, Mar 11, 2021

Filed:

Nov 12, 2020

Appl. No.:

17/096755

Inventors:

- Salt Lake City UT, US
Alexander Gutin - Salt Lake City UT, US
Susanne Wagner - Salt Lake City UT, US
Julia Reid - Salt Lake City UT, US

Assignee:

MYRIAD GENETICS, INC. - Salt Lake City UT

International Classification:

C12Q 1/6886

Abstract:

Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.